Vera Therapeutics, Inc. (VERA) Earnings History
Net Loss7 years of earnings data (2019–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Vera Therapeutics, Inc. (VERA) Earnings Overview
As of November 8, 2026, Vera Therapeutics, Inc. (VERA) reported trailing twelve-month net income of -$415M, reflecting -69.5% year-over-year growth. The company earned $-5.76 per diluted share over the past four quarters.
Looking at the long-term picture, VERA's historical earnings data spans multiple years. The company achieved its highest annual net income of -$12M in fiscal 2019.
Vera Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including CLDX (-$309M net income, -17253.3% margin), HALO ($485M net income, 22.7% margin), PRAX (-$339M net income), VERA has comparable earnings metrics. Compare VERA vs CLDX →
VERA Earnings vs Peers
Earnings metrics vs comparable public companies
VERA Historical Earnings Data (2019–2025)
7 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$300M | -96.9% | -$315M | $-4.66 | - | - |
| 2024 | -$152M | -58.5% | -$167M | $-2.75 | - | - |
| 2023 | -$96M | -7.8% | -$102M | $-2.25 | - | - |
| 2022 | -$89M | -173.1% | -$91M | $-3.35 | - | - |
| 2021 | -$33M | +38.9% | -$34M | $-2.43 | - | - |
| 2020 | -$53M | -350.6% | -$48M | $-14.40 | - | - |
| 2019 | -$12M | - | -$12M | $-3.46 | - | - |
Download Data
Export VERA earnings history in CSV or JSON format
Free sign-in required to download data
VERA Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
7+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
VERA — Frequently Asked Questions
Quick answers to the most common questions about buying VERA stock.
What is VERA earnings per share (EPS)?
VERA trailing twelve-month (TTM) diluted EPS is $-5.76, reflecting -69.5% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2019 to 2025 is available in the table on this page.
What is Vera Therapeutics, Inc.'s net income?
Vera Therapeutics, Inc. (VERA) trailing twelve-month net income is $-415M as of 2025. Earnings declined -69.5% year-over-year.
Is VERA profitable?
VERA is not currently profitable on a TTM basis, reporting a net loss of $-415M. Net margin is N/A. Investors should monitor for a return to profitability.
What is VERA's earnings growth rate?
VERA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2019 to 2025.
What are VERA's profit margins?
Vera Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -50.7%.
Is VERA growing earnings?
VERA earnings are declining — EPS fell -69.5% year-over-year. TTM net income dropped to $-415M. This contrasts with the 5-year CAGR of N/A.
What was VERA's best earnings year?
Vera Therapeutics, Inc.'s highest annual net income on record is $-12M, achieved in fiscal year 2019. Earnings history on this page spans 2019 to 2025 and includes all annual and quarterly figures.
What were VERA's earnings last quarter?
VERA's most recent reported quarter was Q3 2026. Net income was $-94M with diluted EPS of $-1.30. For a full breakdown of all quarters, see the quarterly earnings table on this page.